Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease
AssigneesSeattle Children's Hospital d/b/a Seattle Children's Research Institute, Fred Hutchinson Cancer Research Center
InventorsSihoun Hahn, Sunhee Jung, Jeffrey Whiteaker, Troy Torgerson, Amanda Paulovich, Christopher Collins, Remwilyn Dayuha
Life of this patent
Estimating the term…
Abstract
Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.
Claims177
A method of screening for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in a subject, the method comprising:
- Obtaining a dried blood spot (DBS) sample derived from the subject;
- Digesting proteins from blood of the DBS with an enzyme to yield one or more peptides;
- Enriching for:
- a CD3ε signature peptide of SCID of SEQ ID NO:
- 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 22, CDR2 of SEQ ID NO:
- 23, and CDR3 of SEQ ID NO:
- 24, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 25, CDR2 of SEQ ID NO:
- 26, and CDR3 of SEQ ID NO:
- 27;
- a first WASp signature peptide of WAS of SEQ ID NO:
- 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 28, CDR2 of SEQ ID NO:
- 29, and CDR3 of SEQ ID NO:
- 30, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 31, CDR2 of SEQ ID NO:
- 32, and CDR3 of SEQ ID NO:
- 33;
- a second WASp signature peptide of WAS of SEQ ID NO:
- 3 with an antibody or antigen-binding fragment thereof that binds the second WASp signature peptide;
- a first BTK signature peptide of XLA of SEQ ID NO:
- 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 34, CDR2 of SEQ ID NO:
- 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 36, CDR2 of SEQ ID NO:
- 37, and CDR3 of SEQ ID NO:
- 38;
- and/or
- a second BTK signature peptide of XLA of SEQ ID NO:
- 5 with an antibody or antigen-binding fragment thereof that binds the second BTK signature peptide;
- Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine concentrations of the peptides;
- and
- Diagnosing the subject with:
- SCID when the concentration of the CD3ε signature peptide is lower than a predetermined threshold concentration or when the CD3ε signature peptide is absent;
- WAS when the concentrations of the first and/or second WASp signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second WASp signature peptides are absent;
- and
- XLA when the concentrations of the first and/or second BTK signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second BTK signature peptides are absent.
A method of screening for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in a subject, the method comprising:
- Obtaining a dried blood spot (DBS) sample derived from the subject;
- Digesting proteins from blood of the DBS with an enzyme to yield one or more peptides;
- Enriching for:
- a CD3ε signature peptide of SCID of SEQ ID NO:
- 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 22, CDR2 of SEQ ID NO:
- 23, and CDR3 of SEQ ID NO:
- 24, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 25, CDR2 of SEQ ID NO:
- 26, and CDR3 of SEQ ID NO:
- 27;
- a first WASp signature peptide of WAS of SEQ ID NO:
- 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 28, CDR2 of SEQ ID NO:
- 29, and CDR3 of SEQ ID NO:
- 30, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 31, CDR2 of SEQ ID NO:
- 32, and CDR3 of SEQ ID NO:
- 33;
- a second WASp signature peptide of WAS of SEQ ID NO:
- 3 with an antibody or antigen-binding fragment thereof that binds the second WASp signature peptide;
- a first BTK signature peptide of XLA of SEQ ID NO:
- 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 34, CDR2 of SEQ ID NO:
- 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 36, CDR2 of SEQ ID NO:
- 37, and CDR3 of SEQ ID NO:
- 38;
- and/or
- a second BTK signature peptide of XLA of SEQ ID NO:
- 5 with an antibody or antigen-binding fragment thereof that binds the second BTK signature peptide;
- Enriching for an endogenous ATP7B peptide of:
- SEQ ID NO:
- 10 with an antibody or antigen binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 10;
- SEQ ID NO:
- 11 or 21 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 11 or 21 and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 57, CDR2 of SEQ ID NO:
- 58, and CDR3 of SEQ ID NO:
- 59, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 60, CDR2 of SEQ ID NO:
- 61, and CDR3 of SEQ ID NO:
- 62;
- SEQ ID NO:
- 16 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 16;
- SEQ ID NO:
- 17 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 17;
- SEQ ID NO:
- 18 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 18;
- SEQ ID NO:
- 19 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 19;
- SEQ ID NO:
- 20 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 20;
- or
- SEQ ID NO:
- 21 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO:
- 21;
- Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine concentrations of the peptides;
- Calculating a ratio of signature peptide concentration:endogenous ATP7B peptide concentration for each signature peptide;
- and
- Diagnosing the subject with:
- SCID when the ratio of CD3ε signature peptide concentration:endogenous ATP7B peptide concentration is lower than a corresponding predetermined threshold ratio or when the CD3ε signature peptide is absent;
- WAS when the ratios of the first and/or second WASp signature peptide concentration:endogenous ATP7B peptide concentration are lower than corresponding predetermined threshold ratios or when the first and/or second WASp signature peptides are absent;
- and
- XLA when the ratios of the first and/or second BTK signature peptide concentration:endogenous ATP7B peptide concentration are lower than corresponding predetermined threshold ratios or when the first and/or second BTK signature peptides are absent.
A method of detecting one or more signature peptides of severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in one or more dried blood spot (DBS) samples, the method comprising:
- Obtaining the one or more dried blood spot (DBS) samples;
- Digesting proteins from blood of each DBS with an enzyme to yield one or more peptides;
- Enriching for:
- a CD3ε signature peptide of SCID of SEQ ID NO:
- 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 22, CDR2 of SEQ ID NO:
- 23, and CDR3 of SEQ ID NO:
- 24, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 25, CDR2 of SEQ ID NO:
- 26, and CDR3 of SEQ ID NO:
- 27;
- a first WASp signature peptide of WAS of SEQ ID NO:
- 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 28, CDR2 of SEQ ID NO:
- 29, and CDR3 of SEQ ID NO:
- 30, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 31, CDR2 of SEQ ID NO:
- 32, and CDR3 of SEQ ID NO:
- 33;
- a second WASp signature peptide of WAS of SEQ ID NO:
- 3 with an antibody or antigen-binding fragment thereof that binds the second WASp signature peptide;
- a first BTK signature peptide of XLA of SEQ ID NO:
- 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 34, CDR2 of SEQ ID NO:
- 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 36, CDR2 of SEQ ID NO:
- 37, and CDR3 of SEQ ID NO:
- 38;
- and/or
- a second BTK signature peptide of XLA of SEQ ID NO:
- 5 with an antibody or antigen-binding fragment thereof that binds the second BTK signature peptide;
- Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides, thus detecting one or more signature peptides of SCID, WAS, and XLA in one or more DBS samples.
An assay for the screening of severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), X-linked agammaglobulinemia (XLA) in a subject, and/or Wilson Disease (WD), the assay comprising:
- (i) an antibody or antigen-binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 22, CDR2 of SEQ ID NO:
- 23, and CDR3 of SEQ ID NO:
- 24, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 25, CDR2 of SEQ ID NO:
- 26, and CDR3 of SEQ ID NO:
- 27 that binds to a CD3ε signature peptide of SCID of SEQ ID NO:
- 1;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 28, CDR2 of SEQ ID NO:
- 29, and CDR3 of SEQ ID NO:
- 30, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 31, CDR2 of SEQ ID NO:
- 32, and CDR3 of SEQ ID NO:
- 33 that binds to a WASp signature peptide of WAS of SEQ ID NO:
- 2;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 34, CDR2 of SEQ ID NO:
- 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 36, CDR2 of SEQ ID NO:
- 37, and CDR3 of SEQ ID NO:
- 38 that binds to a BTK signature peptide of XLA of SEQ ID NO:
- 4;
- and/or
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 57, CDR2 of SEQ ID NO:
- 58, and CDR3 of SEQ ID NO:
- 59, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 60, CDR2 of SEQ ID NO:
- 61, and CDR3 of SEQ ID NO:
- 62 that binds to an ATP7B peptide of SEQ ID NO:
- 11 or 21;
- and/or
- (ii) an antibody or antigen-binding fragment thereof that binds a WASp signature peptide of WAS of SEQ ID NO:
- 3;
- an antibody or antigen-binding fragment thereof that binds a BTK signature peptide of XLA of SEQ ID NO:
- 5;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 10;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 16;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 17;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 18;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 19;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 20;
- and/or
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 21;
- and/or
- (iii) reference signature peptides comprising:
- a CD3ε peptide of SCID of SEQ ID NO:
- 1;
- a WASp peptide of WAS of SEQ ID NO:
- 2;
- a WASp peptide of WAS of SEQ ID NO:
- 3;
- a BTK peptide of XLA of SEQ ID NO:
- 4;
- a BTK peptide of XLA of SEQ ID NO:
- 5;
- an ATP7B peptide of WD of SEQ ID NO:
- 10;
- an ATP7B peptide of WD of SEQ ID NO:
- 11;
- an ATP7B peptide of WD of SEQ ID NO:
- 16;
- an ATP7B peptide of WD of SEQ ID NO:
- 17;
- an ATP7B peptide of WD of SEQ ID NO:
- 18;
- an ATP7B peptide of WD of SEQ ID NO:
- 19;
- an ATP7B peptide of WD of SEQ ID NO:
- 20;
- and/or
- an ATP7B peptide of WD of SEQ ID NO:
- 21.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 22, CDR2 of SEQ ID NO:
- 23, and CDR3 of SEQ ID NO:
- 24, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 25, CDR2 of SEQ ID NO:
- 26, and CDR3 of SEQ ID NO:
- 27.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 28, CDR2 of SEQ ID NO:
- 29, and CDR3 of SEQ ID NO:
- 30, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 31, CDR2 of SEQ ID NO:
- 32, and CDR3 of SEQ ID NO:
- 33.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 34, CDR2 of SEQ ID NO:
- 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 36, CDR2 of SEQ ID NO:
- 37, and CDR3 of SEQ ID NO:
- 38.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 39, CDR2 of SEQ ID NO:
- 40, and CDR3 of SEQ ID NO:
- 41, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 42, CDR2 of SEQ ID NO:
- 43, and CDR3 of SEQ ID NO:
- 44.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 45, CDR2 of SEQ ID NO:
- 46, and CDR3 of SEQ ID NO:
- 47, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 48, CDR2 of SEQ ID NO:
- 49, and CDR3 of SEQ ID NO:
- 50.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 51, CDR2 of SEQ ID NO:
- 52, and CDR3 of SEQ ID NO:
- 53, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 54, CDR2 of SEQ ID NO:
- 55, and CDR3 of SEQ ID NO:
- 56.
An isolated antibody or antigen binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 57, CDR2 of SEQ ID NO:
- 58, and CDR3 of SEQ ID NO:
- 59, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 60, CDR2 of SEQ ID NO:
- 61, and CDR3 of SEQ ID NO:
- 62.
A kit comprising:
- (i) an antibody or antigen-binding fragment thereof comprising:
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 22, CDR2 of SEQ ID NO:
- 23, and CDR3 of SEQ ID NO:
- 24, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 25, CDR2 of SEQ ID NO:
- 26, and CDR3 of SEQ ID NO:
- 27 that binds to a CD3ε signature peptide of SCID of SEQ ID NO:
- 1;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 28, CDR2 of SEQ ID NO:
- 29, and CDR3 of SEQ ID NO:
- 30, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 31, CDR2 of SEQ ID NO:
- 32, and CDR3 of SEQ ID NO:
- 33 that binds to a WASp signature peptide of WAS of SEQ ID NO:
- 2;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 34, CDR2 of SEQ ID NO:
- 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 36, CDR2 of SEQ ID NO:
- 37, and CDR3 of SEQ ID NO:
- 38 that binds to a BTK signature peptide of XLA of SEQ ID NO:
- 4;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 39, CDR2 of SEQ ID NO:
- 40, and CDR3 of SEQ ID NO:
- 41, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 42, CDR2 of SEQ ID NO:
- 43, and CDR3 of SEQ ID NO:
- 44 that binds to a CTNS signature peptide of cystinosis of SEQ ID NO:
- 6;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 45, CDR2 of SEQ ID NO:
- 46, and CDR3 of SEQ ID NO:
- 47, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 48, CDR2 of SEQ ID NO:
- 49, and CDR3 of SEQ ID NO:
- 50 that binds to a CTNS signature peptide of cystinosis of SEQ ID NO:
- 7 or 8;
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 51, CDR2 of SEQ ID NO:
- 52, and CDR3 of SEQ ID NO:
- 53, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 54, CDR2 of SEQ ID NO:
- 55, and CDR3 of SEQ ID NO:
- 56 that binds to a SHPK signature peptide of cystinosis of SEQ ID NO:
- 9;
- and/or
- a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO:
- 57, CDR2 of SEQ ID NO:
- 58, and CDR3 of SEQ ID NO:
- 59, and a light chain variable (VL) domain comprising:
- CDR1 of SEQ ID NO:
- 60, CDR2 of SEQ ID NO:
- 61, and CDR3 of SEQ ID NO:
- 62 that binds to an ATP7B peptide of SEQ ID NO:
- 11 or 21;
- and/or
- (ii) an antibody or antigen-binding fragment thereof that binds a WASp signature peptide of WAS of SEQ ID NO:
- 3;
- an antibody or antigen-binding fragment thereof that binds a BTK signature peptide of XLA of SEQ ID NO:
- 5;
- an antibody or antigen-binding fragment thereof that binds a CTNS signature peptide of SEQ ID NO:
- 12;
- an antibody or antigen-binding fragment thereof that binds a CTNS signature peptide of SEQ ID NO:
- 13;
- an antibody or antigen-binding fragment thereof that binds a SHPK signature peptide of SEQ ID NO:
- 14;
- an antibody or antigen-binding fragment thereof that binds a SHPK signature peptide of SEQ ID NO:
- 15;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 10;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 16;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 17;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 18;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 19;
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 20;
- and/or
- an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO:
- 21;
- and/or
- (iii) reference signature peptides comprising:
- a CD3ε peptide of SCID of SEQ ID NO:
- 1;
- a WASp peptide of WAS of SEQ ID NO:
- 2;
- a WASp peptide of WAS of SEQ ID NO:
- 3;
- a BTK peptide of XLA of SEQ ID NO:
- 4;
- a BTK peptide of XLA of SEQ ID NO:
- 5;
- a CTNS peptide of cystinosis of SEQ ID NO:
- 6;
- a CTNS peptide of cystinosis of SEQ ID NO:
- 7 or 8;
- a CTNS peptide of cystinosis of SEQ ID NO:
- 12;
- a CTNS peptide of cystinosis of SEQ ID NO:
- 13;
- a SHPK peptide of cystinosis of SEQ ID NO:
- 9;
- a SHPK peptide of cystinosis of SEQ ID NO:
- 14;
- a SHPK peptide of cystinosis of SEQ ID NO:
- 15;
- an ATP7B peptide of WD of SEQ ID NO:
- 10;
- an ATP7B peptide of WD of SEQ ID NO:
- 11;
- an ATP7B peptide of WD of SEQ ID NO:
- 16;
- an ATP7B peptide of WD of SEQ ID NO:
- 17;
- an ATP7B peptide of WD of SEQ ID NO:
- 18;
- an ATP7B peptide of WD of SEQ ID NO:
- 19;
- an ATP7B peptide of WD of SEQ ID NO:
- 20;
- and/or
- an ATP7B peptide of WD of SEQ ID NO:
- 21.
A method of screening for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), X-linked agammaglobulinemia (XLA), cystinosis, and/or Wilson disease (WD) in a subject, the method comprising:
- Obtaining a dried blood spot (DBS) sample derived from the subject;
- Digesting proteins from blood of the DBS with an enzyme to yield one or more peptides;
- Enriching for:
- a CD3ε signature peptide of SCID with an antibody or antigen-binding fragment thereof that binds to the CD3ε signature peptide;
- a first WASp signature peptide of WAS with an antibody or antigen-binding fragment thereof that binds to the first WASp signature peptide;
- a second WASp signature peptide of WAS with an antibody or antigen-binding fragment thereof that binds to the second WASp signature peptide;
- a first BTK signature peptide of XLA with an antibody or antigen-binding fragment thereof that binds to the first BTK signature peptide;
- a second BTK signature peptide with an antibody or antigen-binding fragment thereof that binds to the second BTK signature peptide;
- a first CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the first CTNS signature peptide;
- a second CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the second CTNS signature peptide;
- a third CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the third CTNS signature peptide;
- a fourth CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the fourth CTNS signature peptide;
- a first SHPK signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the first SHPK signature peptide;
- a second SHPK signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the second SHPK signature peptide;
- and/or
- a third SHPK signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the third SHPK signature peptide;
- a first ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the first ATP7B signature peptide;
- a second ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the second ATP7B signature peptide;
- a third ATP7B signature peptide with an antibody or antigen-binding fragment that binds to the third ATP7B signature peptide;
- a fourth ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the fourth ATP7B signature peptide;
- a fifth ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the fifth ATP7B signature peptide;
- a sixth ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the sixth ATP7B signature peptide;
- and/or
- a seventh ATP7B signature peptide with an antibody or antigen-binding fragment thereof;
- Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine concentrations of the peptides;
- and
- Diagnosing the subject with:
- SCID when the concentration of the CD3ε signature peptide is lower than a predetermined threshold concentration or when the CD3ε signature peptide is absent;
- WAS when the concentrations of the first and/or second WASp signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second WASp signature peptides are absent;
- XLA when the concentrations of the first and/or second BTK signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second BTK signature peptides are absent;
- cystinosis when the concentrations of the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are lower than corresponding predetermined threshold concentrations or when the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are absent;
- and/or
- WD when the concentrations of the first ATP7B, the second ATP7B, the third ATP7B, the fourth ATP7B, the fifth ATP7B, the sixth ATP7B, and/or the seventh ATP7B signature peptides are lower than corresponding predetermined threshold concentrations or when the first ATP7B, the second ATP7B, the third ATP7B, the fourth ATP7B, the fifth ATP7B, the sixth ATP7B, and/or the seventh ATP7B signature peptides are absent.
Dependencies are inferred from the claim text.